A retrospective study of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma
Latest Information Update: 30 Aug 2021
At a glance
- Drugs Axitinib (Primary) ; Pembrolizumab (Primary) ; Toripalimab (Primary)
- Indications Malignant melanoma; Mouth neoplasm; Oesophageal cancer; Urogenital cancer
- Focus Therapeutic Use
- 30 Aug 2021 New trial record
- 20 Aug 2021 Results published in the European Journal of Cancer